BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
Health and Human Services (all) · BARDA - ASPR / DAAPPO / BARDA DCMA
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75A50126C00005 in this department, oldest first.
- Apr 27, 2026 · this noticeAward NoticeISOLA THERAPEUTICS INC · $7.5M
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
What the notice says
The purpose of the proposed Contract is for Nebulization Therapy to Prevent and Treat Pulmonary Foam Caused by Inhaled Chemical Agents. The primary goal of the R&D effort described in this statement of work (SOW) is to generate the necessary data and information to support an initial FDA meeting to align on the regulatory strategy. The contract scope includes early-stage formulation and analytical development of the drug product; nebulizer characterization including flow rates and particle size distribution; bioanalytical development to support non-GLP studies using the proposed test article i… (show all)
ncluding PK, dose range finding, and chlorine exposure proof-of-concept (POC); and development of an overall regulatory strategy. This scope of work is expected to support a productive FDA engagement and advance the technical readiness level (TRL) through TRL 5 to meet minimum requirements to support various future contract vehicles. The generated data and completed non-GLP studies, along with FDA feedback, will inform work required in later development phases.
Who won similar work
4 award notices on SAM.gov in the last 24 months. Matched by: Same office (BARDA - ASPR / DAAPPO / BARDA DCMA), same product/service code (PSC) AN13 and NAICS 541714.
Single-winner award sizes (4): middle half $99.4M to $224.3M, median $142.9M; range $98.6M to $339.2M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| CIDARA THERAPEUTICS INC | 1 | $339.2M | Oct 14, 2025 |
| RAFA LABORATORIES LTD | 1 | $186.0M | Oct 1, 2025 |
| Flosonics Medical LLC | 1 | $99.7M | Jun 5, 2026 |
| OSIVAX Paris 8 �le-de-France 75008 FRA | 1 | $98.6M | Oct 14, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Jun 5, 2026Flosonics Medical LLC$99.7MBiomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
- Oct 14, 2025OSIVAX Paris 8 �le-de-France 75008 FRA$98.6MClinical Proof of Concept of OVX836, a single-shot broadly protective Influenza A vaccine for immediate protection against emerging pandemic strains
- Oct 14, 2025CIDARA THERAPEUTICS INC$339.2MDevelopment of CD388 as a long-lasting prophylactic anti-viral option for protection against the health impacts caused by influenza
- Oct 1, 2025RAFA LABORATORIES LTD$186.0MDevelopment Of a Concentrated Tranexamic Acid (TXA) Intramuscular Injection
Competitive landscape
For the 4 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Health & Human Services, Dept of (HHS) since 2024 (3 filings)
- 0 of their lobbyists list a past Health & Human Services, Dept of (HHS) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 252 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.